Detalhe da pesquisa
1.
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
N Engl J Med
; 379(22): 2097-2107, 2018 11 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-30403574
2.
Effect of Alirocumab on Mortality After Acute Coronary Syndromes.
Circulation
; 140(2): 103-112, 2019 07 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31117810
3.
Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial.
Eur Heart J
; 40(33): 2801-2809, 2019 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31121022
4.
No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data.
Eur Heart J
; 39(5): 374-381, 2018 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29186504
5.
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
Am Heart J
; 168(5): 682-9, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25440796
6.
Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial.
JAMA
; 310(11): 1145-55, 2013 Sep 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-23995608
7.
Design and rationale of the treatment of acute coronary syndromes with otamixaban trial: a double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non-ST-segment elevation acute coronary syndromes with a planned early invasive strategy.
Am Heart J
; 164(6): 817-24.e13, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23194481
8.
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.
J Am Coll Cardiol
; 75(2): 133-144, 2020 01 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31948641
9.
Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial.
J Am Coll Cardiol
; 74(9): 1167-1176, 2019 09 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30898609
10.
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial.
J Am Coll Cardiol
; 73(4): 387-396, 2019 02 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30428396
11.
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.
Lancet Diabetes Endocrinol
; 7(8): 618-628, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31272931
12.
Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery.
J Am Coll Cardiol
; 74(9): 1177-1186, 2019 09 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31466614